CommunitiesHER2+Switching from Phesgo to Hyalecta for HER2+ Breast Cancer: Any Experiences?

Switching from Phesgo to Hyalecta for HER2+ Breast Cancer: Any Experiences?

GK

Community Member

7 months ago

Hello, Has anyone switched from Phesgo (Herceptin plus Perjeta) to Hyalecta (Herceptin injection with Perjeta)? I have very stable oligiometastatic her2+ with only one small Mets to bone that hasn’t changed in 4 years. Itching is getting to be too much. Oncologist suggested dropping Perjeta - likely cause of the itching - and continuing the close monitoring. That idea makes me anxious since it’s the combo that’s worked so well. Anyone have experience with this? Thank you. Grace.

4 comments
Comment
accepted answer

Accepted Answer

That sounds like a challenging situation to navigate, especially when the current treatment combination has been working so well. Many patients in the HER2+ community face similar decisions about managing side effects while maintaining effective treatment. Connecting with others who have experience with these specific medications or have faced comparable treatment decisions could provide valuable insights as you work through this with your oncologist.

3+ patients found this helpful

CD

Community Member

6 months ago

I did have the itching side effect with Perheta & Herceptin to the point I would have a raised rash all down my right arm. My Dr. treated me with a regiment of antihistamines. I would have to put an ice pack on my arm just to relieve the itching. It was so bad once I started taking the antihistamines. It seemed to do the trick.

JA

Community Member

6 months ago

I have had this exact situation. I have oliigiometastatic breast cancer that is her2 triple positive. I have one small met in my femur that was treated with radiation. I was diagnosed in 2019 and I have been NID since 2020. Perjeta has caused some bothersome side effects, and the doctor has given me a choice to eliminate Perjeta. I have just chosen to pause Perjeta temporarily to see if that gets rid of the side effects. We will continue monitoring probably by circulating tumor cells, and add back Perjeta if needed.

GK

Community Member

6 months ago

Thanks for responding. It’s helpful.

CA

Community Member

2 months ago

That sounds like a challenging situation to navigate, especially when the current treatment combination has been working so well. Many patients in the HER2+ community face similar decisions about managing side effects while maintaining effective treatment. Connecting with others who have experience with these specific medications or have faced comparable treatment decisions could provide valuable insights as you work through this with your oncologist.

Outcomes4Me

© 2025 Outcomes4Me Inc. All rights reserved.